Literature DB >> 10855770

T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.

S R Riddell1, P D Greenberg.   

Abstract

Acute and persistent virus infections are limited by the development and maintenance of host T-cell responses to viral antigens. Individuals with congenital or acquired immunodeficiencies are at risk of progressive and often life-threatening infection. Recent studies have provided insight into the nature of protective T-cell responses to viruses and advances in T-cell culture technology have made it possible to evaluate the adoptive transfer of T-cell clones of defined antigen specificity and function to restore deficient responses in immunocompromised hosts. The progress of these studies in cytomegalovirus and human immunodeficiency virus infection is the subject of this review.

Entities:  

Mesh:

Year:  2000        PMID: 10855770     DOI: 10.1093/jac/45.suppl_4.35

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

Authors:  Roman A Tuma; Rielle Giannino; Patrick Guirnalda; Ingrid Leiner; Eric G Pamer
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 2.  Herpesvirus infections in organ transplant recipients.

Authors:  Frank J Jenkins; David T Rowe; Charles R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

3.  Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.

Authors:  Lisa A Jurgens; Rajiv Khanna; James Weber; Rimas J Orentas
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 4.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

5.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen.

Authors:  G Ramadan; B Davies; V P Kurup; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

7.  A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.

Authors:  Christian Andreas Mohr; Jurica Arapovic; Hermine Mühlbach; Marc Panzer; Annelies Weyn; Lars Dölken; Astrid Krmpotic; David Voehringer; Zsolt Ruzsics; Ulrich Koszinowski; Torsten Sacher
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

8.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

9.  Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Authors:  Lin Xia; Ruopeng Su; Zhiqiang An; Tong-Ming Fu; Wenxin Luo
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

Review 10.  DNA vaccines to attack cancer.

Authors:  Freda K Stevenson; Christian H Ottensmeier; Peter Johnson; Delin Zhu; Sarah L Buchan; Katy J McCann; Joanne S Roddick; Andrew T King; Feargal McNicholl; Natalia Savelyeva; Jason Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.